Angiotensin IV analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-15. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Trials are investigating whether botulinum toxin, when used to make a person appear to frown less, stops negative feedback from the face and affects depression. Psilocybin may have a beneficial role in the treatment of depression. A 2019 meta-analysis found that hypnotherapy may be an effective way of alleviating the symptoms of depression. No model of depression in animals that fully explains the mechanism of depression has been found as of 2019.
Three of the entrances took the form of free-standing pavilions or small stations, including waiting rooms: one at Bastille and two on Avenue de Wagram at Étoile. These were in a style influenced by Japanese pagodas. At Étoile Guimard provided exterior doors for elevators, although the elevators were not built. Eight simpler but still elaborate structures, labeled "Édicule B" by Guimard, were installed at the termini of Line 1 as originally opened and at two other major stations. These consisted of three-sided glass-roofed structures enclosing the stairway, with a projecting canopy. A variation on this format, "Édicule A", lacked the canopy and was erected at two stations, Saint-Paul and Reuilly–Diderot. These édicule types of entrance, which have come to be called libellules because they resemble dragonflies, in some cases had decorated wall panels surfaced in reconstituted lava. The great majority of the entrances built (154) were unroofed enclosures, dubbed an entourage. A transitional form between the entourage and the édicule, railings with a roof and canopy, was used for one entrance at the Gare de Lyon metro station. At many of the entourages, the top of the steps is surmounted by a "Métropolitain" or "Métro" sign in a holder that extends between two risers in the form of sinuous stalks, traditionally compared to lily of the valley (brin de muguet), each bearing a light in the form of a red-orange globe reminiscent of an eye or a flower.
Tyrosine is the non-essential amino acid precursor of melanin. Tyrosine is converted to dihydroxyphenylalanine (DOPA) via the enzyme tyrosinase. Then DOPA is polymerized into melanin. The copper-ion based enzyme-catalyzed oxidative transformation of catechol derivative dopa to light absorbing dopaquinone to indole-5,6-quinone is clearly seen following the polymerization to melanin, the color of the pigment ranges from red to dark brown.
Rhodesia began to lose vital economic and military support from South Africa, which, while sympathetic to the white minority government, never accorded it diplomatic recognition. The South African government placed limits on the fuel and munitions they supplied to the Rhodesian military. They also withdrew the personnel and equipment that they had previously provided to aid the war effort, though covert military support continued. In 1976, the South African government and United States governments worked together to place pressure on Smith to agree to a form of majority rule. In response to the initiative of United States Secretary of State Henry Kissinger, in 1976 Ian Smith accepted the principle of black majority rule within two years. The Rhodesians now offered more concessions, but those concessions, focused on reaching an "internal settlement" with moderate black leaders, were insufficient to end the war. At the time, some Rhodesians said the still embittered history between the British-dominated Rhodesia and the Afrikaner-dominated South Africa partly led the South African government to withdraw its aid to Rhodesia. Ian Smith said in his memoirs that even though many white South Africans supported Rhodesia, South African Prime Minister John Vorster's policy of détente with the black African states ended up with Rhodesia being offered as the "sacrificial lamb" to buy more time for South Africa. Other observers perceived South Africa's distancing itself from Rhodesia as being an early move in the process that led to majority rule in South Africa itself.
Sources: en.wikipedia.org
Some bird species undertake shorter migrations, travelling only as far as is required to avoid bad weather or obtain food. Irruptive species such as the boreal finches are one such group and can commonly be found at a location in one year and absent the next. This type of migration is normally associated with food availability. Species may also travel shorter distances over part of their range, with individuals from higher latitudes travelling into the existing range of conspecifics; others undertake partial migrations, where only a fraction of the population, usually females and subdominant males, migrates. Partial migration can form a large percentage of the migration behaviour of birds in some regions; in Australia, surveys found that 44% of non-passerine birds and 32% of passerines were partially migratory. Altitudinal migration is a form of short-distance migration in which birds spend the breeding season at higher altitudes and move to lower ones during suboptimal conditions. It is most often triggered by temperature changes and usually occurs when the normal territories also become inhospitable due to lack of food. Some species may also be nomadic, holding no fixed territory and moving according to weather and food availability. Parrots as a family are overwhelmingly neither migratory nor sedentary but considered to either be dispersive, irruptive, nomadic or undertake small and irregular migrations.
Most remaining forest is found inside reserves and national parks. Habitat destruction has proved a threat for marine life. Illegal fishing is another major threat, with fishing methods such as dynamite fishing and poisoning depleting marine ecosystems. Leatherback turtle numbers have dropped by 98% since the 1950s. Hunting has also been an issue for some animals, with overconsumption and the use of animal parts for profit endangering many animals, from marine life to tigers. Marine life is also detrimentally affected by uncontrolled tourism. The Malaysian government aims to balance economic growth with environmental protection, but has been accused of favouring big business over the environment. Some state governments are now trying to counter the environmental impact and pollution created by deforestation; and the federal government is trying to cut logging by 10% each year. A total of 28 national parks have been established, 23 in East Malaysia and five in the peninsula. Tourism has been limited in biodiverse areas such as the island of Sipadan. Wildlife trafficking is a large issue, and the Malaysian government has held talks with the governments of Brunei and Indonesia to standardise anti-trafficking laws.
In November 1997 National Theatre of Greece launched a worldwide tour of Medea, a critically acclaimed production directed by Nikaiti Kontouri, starring Karyofyllia Karambeti as Medea, Kostas Triantafyllopoulos as Creon and Lazaros Georgakopoulos as Jason. The tour included performances in France, Australia, Israel, Portugal, United States, Canada, Turkey, Bulgaria, China and Japan and lasted almost two years, until July 1999. The play opened in the United States at Shubert Theatre in Boston (18 and 19 September 1998) and then continued at City Center Theatre in Manhattan, New York City (23 to 27 September 1998), receiving a very positive review from The New York Times. Neil LaBute wrote Medea Redux, a modern retelling, first performed in 1999 starring Calista Flockhart, as part of his one-act trilogy entitled Bash: Latter-Day Plays. In this version, the main character is seduced by her middle-school teacher. He abandons her, and she kills their child out of revenge. Michael John LaChiusa created a Broadway musical adaptation work for Audra McDonald entitled Marie Christine in 1999. McDonald portrayed the title role, and the show was set in 1890s New Orleans and Chicago. Liz Lochhead's Medea previewed at the Old Fruitmarket, Glasgow as part of Theatre Babel's Greeks in 2000 before the Edinburgh Fringe and national tour. "What Lochhead does is to recast MEDEA as an episode-ancient but new, cosmic yet agonisingly familiar- in a sex war which is recognisable to every woman, and most of the men, in the theatre", wrote The Scotsman.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.